CA2096723C - Methods and compositions for the suppression of neu mediated transformation - Google Patents

Methods and compositions for the suppression of neu mediated transformation Download PDF

Info

Publication number
CA2096723C
CA2096723C CA002096723A CA2096723A CA2096723C CA 2096723 C CA2096723 C CA 2096723C CA 002096723 A CA002096723 A CA 002096723A CA 2096723 A CA2096723 A CA 2096723A CA 2096723 C CA2096723 C CA 2096723C
Authority
CA
Canada
Prior art keywords
ela
neu
gene
cells
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002096723A
Other languages
English (en)
French (fr)
Other versions
CA2096723A1 (en
Inventor
Mien-Chie Hung
Di-Hua Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of CA2096723A1 publication Critical patent/CA2096723A1/en
Application granted granted Critical
Publication of CA2096723C publication Critical patent/CA2096723C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
CA002096723A 1990-12-04 1991-12-04 Methods and compositions for the suppression of neu mediated transformation Expired - Fee Related CA2096723C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62146590A 1990-12-04 1990-12-04
US621,465 1990-12-04
PCT/US1991/009100 WO1992010573A1 (en) 1990-12-04 1991-12-04 Methods and compositions for the suppression of neu mediated transformation

Publications (2)

Publication Number Publication Date
CA2096723A1 CA2096723A1 (en) 1992-06-05
CA2096723C true CA2096723C (en) 2006-03-28

Family

ID=24490270

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002096723A Expired - Fee Related CA2096723C (en) 1990-12-04 1991-12-04 Methods and compositions for the suppression of neu mediated transformation

Country Status (11)

Country Link
US (1) US5651964A (cg-RX-API-DMAC7.html)
EP (1) EP0560932B1 (cg-RX-API-DMAC7.html)
JP (2) JPH06504671A (cg-RX-API-DMAC7.html)
AT (1) ATE142261T1 (cg-RX-API-DMAC7.html)
AU (1) AU651650B2 (cg-RX-API-DMAC7.html)
CA (1) CA2096723C (cg-RX-API-DMAC7.html)
DE (1) DE69121903T2 (cg-RX-API-DMAC7.html)
DK (1) DK0560932T3 (cg-RX-API-DMAC7.html)
ES (1) ES2093248T3 (cg-RX-API-DMAC7.html)
GR (1) GR3021805T3 (cg-RX-API-DMAC7.html)
WO (1) WO1992010573A1 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641484A (en) * 1990-12-04 1997-06-24 Board Of Regents, The University Of Texas System Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen
US5643567A (en) * 1990-12-04 1997-07-01 Board Of Regents, The University Of Texas System Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen
US5516631A (en) * 1992-10-13 1996-05-14 La Jolla Cancer Research Foundation Method of inhibiting replication of hyperproliferative cells
AU5962694A (en) * 1992-12-31 1994-08-15 Exemplar Corporation Producing cells for transplantation to reduce host rejection and resulting cells
US5776743A (en) 1994-09-06 1998-07-07 La Jolla Cancer Research Foundation Method of sensitizing tumor cells with adenovirus E1A
US6326356B1 (en) * 1996-10-18 2001-12-04 Board Of Regents, The University Of Texas System Suppression of neu overexpression using a mini-E1A gene
US6008202A (en) * 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5763415A (en) * 1995-08-03 1998-06-09 John Hopkins University School Of Medicine Destruction of the epithelium of an exocrine gland in the prophylactic and therapeutic treatment of cancer
US6861506B1 (en) 1996-01-11 2005-03-01 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
US6828431B1 (en) 1999-04-09 2004-12-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US7241876B2 (en) 1996-01-11 2007-07-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6656480B2 (en) 1996-01-11 2003-12-02 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
CA2250222A1 (en) * 1996-03-20 1997-09-25 Mien-Chie Hung Sensitization of her-2/neu overexpressing cancer cells to chemotherapy
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
US7049410B2 (en) * 1999-05-14 2006-05-23 Majumdar Adhip P N Antibodies to a novel EGF-receptor related protein (ERRP)
US6399743B1 (en) 1999-05-14 2002-06-04 Dept. Of Veterans Affairs Isolation and characterization of a rat epidermal growth factor related protein
US9486429B2 (en) 1999-06-01 2016-11-08 Vanderbilt University Therapeutic methods employing nitric oxide precursors
US6346382B1 (en) 1999-06-01 2002-02-12 Vanderbilt University Human carbamyl phosphate synthetase I polymorphism and diagnostic methods related thereto
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
BR0013814A (pt) 1999-08-27 2002-04-23 Genentech Inc Métodos de tratamentos de um paciente humano suscetìvel a ou diagnosticado com uma doença com anticorpos anti-erbb2, artigos industrializados, métodos de tratamentos de câncer em pacientes humanos e usos do anticorpo anti-erbb2
US20040086903A1 (en) * 2000-12-29 2004-05-06 Jean-Jacques Lareyre Epididymal lipocalin gene and uses thereof
US20020169126A1 (en) * 2001-03-21 2002-11-14 Mien-Chie Hung Compositions and methods for inactivating the Akt oncogene and/or activating the p38 pro-apoptotic gene
US20050069918A1 (en) 2003-05-29 2005-03-31 Francois Claret JAB1 as a prognostic marker and a therapeutic target for human cancer
US20100132058A1 (en) 2004-07-23 2010-05-27 Diatchenko Luda B Methods and materials for determining pain sensitivity and predicting and treating related disorders
PT2247297T (pt) * 2008-01-31 2019-04-24 Univ Vanderbilt Tratamento terapêutico para estados pulmonares
HUE045571T2 (hu) 2008-01-31 2020-01-28 Univ Vanderbilt Koronáriás és artériás aneurizmás szubarachnoideális vérzés kezelésére szolgáló eljárások és készítmények

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
ES2067755T3 (es) * 1989-06-22 1995-04-01 Vestar Inc Proceso de encapsulado.
ATE237694T1 (de) * 1991-08-20 2003-05-15 Us Gov Health & Human Serv Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
US5496731A (en) * 1993-03-25 1996-03-05 Xu; Hong-Ji Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy

Also Published As

Publication number Publication date
DE69121903D1 (de) 1996-10-10
EP0560932A1 (en) 1993-09-22
AU651650B2 (en) 1994-07-28
ATE142261T1 (de) 1996-09-15
DK0560932T3 (cg-RX-API-DMAC7.html) 1997-02-17
CA2096723A1 (en) 1992-06-05
JP2002114707A (ja) 2002-04-16
JP3323491B2 (ja) 2002-09-09
WO1992010573A1 (en) 1992-06-25
JPH06504671A (ja) 1994-06-02
AU9146991A (en) 1992-07-08
ES2093248T3 (es) 1996-12-16
GR3021805T3 (en) 1997-02-28
US5651964A (en) 1997-07-29
DE69121903T2 (de) 1997-04-10
EP0560932B1 (en) 1996-09-04

Similar Documents

Publication Publication Date Title
CA2096723C (en) Methods and compositions for the suppression of neu mediated transformation
Yu et al. Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products.
US5814315A (en) Methods for the suppression of neu mediated phenotype in tumors
US5641484A (en) Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen
Pozzatti et al. The human T-lymphotropic virus type I tax gene can cooperate with the ras oncogene to induce neoplastic transformation of cells
Yu et al. Adenovirus type 5 E1A gene products act as transformation suppressors of the neu oncogene
Phelps et al. The human papillomavirus type 16 E7 gene encodes transactivation and transformation functions similar to those of adenovirus E1A
Iftner et al. Involvement of human papillomavirus type 8 genes E6 and E7 in transformation and replication
Santoso et al. Adenovirus-based p53 gene therapy in ovarian cancer
Suen et al. c-myc reverses neu-induced transformed morphology by transcriptional repression
Matlashewski et al. Transformation of primary human fibroblast cells with human papillomavirus type 16 DNA and EJ‐ras
EP0951553B1 (en) Adenovirus e4 proteins for inducing cell death
Chang et al. Suppression of transcription activity of the MEQ protein of oncogenic Marek's disease virus serotype 1 (MDV1) by L-MEQ of non-oncogenic MDV1
Kiyono et al. The primary structure of major viral RNA in a rat cell line transfected with type 47 human papillomavirus DNA and the transforming activity of its cDNA and E6 gene
Corallini et al. Induction of malignant subcutaneous sarcomas in hamsters by a recombinant DNA containing BK virus early region and the activated human c-Harvey-ras oncogene
Kuzumaki et al. Resistance to oncogenic transformation in revertant R1 of human ras-transformed NIH 3T3 cells
Timmers et al. Adenovirus E1A represses transcription of the cellular JE gene
Telling et al. Constructing chimeric type 12/type 5 adenovirus E1A genes and using them to identify an oncogenic determinant of adenovirus type 12
Grim et al. erbB-2 knockout employing an intracellular single-chain antibody (sFv) accomplishes specific toxicity in erbB-2-expressing lung cancer cells.
Murphy et al. Definition of a region required for transformation in E1a of adenovirus 12
Lerman et al. DNA sequences in human nasopharyngeal carcinoma cells that specify susceptibility to tumor promoter-induced neoplastic transformation
Ohman et al. Effect of adenovirus-2 early region-4 products on e1-transformation
Yu Repression ofneu oncogene by E1A: Mechanisms and biological functions
Jannun et al. Functional relatedness between the E1a and E1b regions of group C and group D human adenoviruses
Li The methylation patterns of Bovine papillomavirus DNA in LM (tk (-)) cells

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed